SR One leads $55M round for nasal alternative to EpiPen; Sanofi pulls website over accuracy concerns
California-based biopharma company ARS Pharmaceuticals said today that they have closed on a Series D round of $55 million. The round was led by SR One, with RA Capital Management and Deerfield Management participating.
ARS is using the money to advance its drug Neffy, an epinephrine nasal spray, through FDA approval and initial launch to consumers as an easy-to-use alternative to EpiPen for severe allergic reactions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.